Home Uncategorized Page 9

Uncategorized

Latest

William Leonard Pickard interviews Bryan Hubbard about the new policy frontier of Ibogaine

Psychedelic legend “the Acid King” William Leonard Pickard Announced as Keynote Speaker at the 2025 North Florida Entheogenic Conference

atai Life Sciences to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Conference

atai Life Sciences Announces Update on Beckley Psytech’s Phase 1/2a Trial of ELE-101 (IV Psilocin) for Major Depressive Disorder, with Initial Results from Phase...

William Leonard Pickard participating in celebration for Sasha Shulgin’s new book...

Tryp Therapeutics Partners with Clinlogix for Clinical Trial Support

Henrik Dahl’s Review of Pickard’s ‘The Rose of Paracelsus: On Secrets...

Markets for Feb 26: $AION +8.33%, $CYBN -19.19%, $FTRP -13.09%

Psychedelic Spotlight: Entheon Biomedical

1...8910...13 Page 9 of 13

Pα+ Psychedelic Bulletin #207: Lykos Rebrands to Resilient; Pharma Pushes Back...

Matt Xavier -The Psychedelic DJ

AbbVie to Acquire Gilgamesh’s Bretisilocin for Up to $1.2B

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Uncategorized

William Leonard Pickard interviews Bryan Hubbard about the new policy frontier of Ibogaine

Psychedelic legend “the Acid King” William Leonard Pickard Announced as Keynote Speaker at the 2025 North Florida Entheogenic Conference

Hello world!

atai Life Sciences to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Conference

atai Life Sciences Announces Update on Beckley Psytech’s Phase 1/2a Trial of ELE-101 (IV Psilocin) for Major Depressive Disorder, with Initial Results from Phase...

November 2020 Newsletter

Sept/Oct 2020 Newsletter

July 2020 Newsletter

June 2020 Newsletter

CLINICAL RESEARCH ASSOCIATE